Pipeline

ABL105

HomePipelineABL105

  • Pipeline
    ABL105
  • Program Target
    HER2x4-1BB
  • Disease Indication
    Solid Tumor
  • Development Stage
    IND Submission
Summary
ABL105 is a bispecific antibody that simultaneously targets HER2 and 4-1BB, crosslinking and activating 4-1BB signaling only when in the presence of tumor cells. Done so in an HER2 expression-dependent manner, ABL105 does not induce T-cell activation in normal tissues lacking 4-1BB clustering. In addition, ABL105 blocks HER2 signaling and induces NK cell-mediated cytotoxicity, leading to stronger anti-tumor activity. ABL105 significantly inhibits tumor growth and protects mice from tumor recurrence by inducing tumor specific memory.

MOA of ABL105

ABL105 in the Grabody™-T BsAb Platform activates T-cells only in the Tumor Microenvironment

MOA of ABL105
MOA of ABL105

Tumor Specific 4-1BB Activation

ABL105 activates 4-1BB signaling only in the presence of tumor cells in a HER2 expression-dependent manner

Tumor Specific 4-1BB Activation
Tumor Specific 4-1BB Activation

Strong Anti-Tumor Effect

ABL105 inhibits tumor growth and protects mice from tumor re-challenge by inducing tumor specific memory

Strong Anti-Tumor Effect
좌우스크롤 Strong Anti-Tumor Effect

Posters

좌우스크롤
Posters(Pipeline, Name, Title, PDF)
Pipeline Name Title PDF
ABL105 ESMO A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation PDF 아이콘